



Public Testimony Registration

1 message

PSWebteam@magellanhealth.com <PSWebteam@magellanhealth.com>
To: AHCCCSParmacyDept@azahcccs.gov, douikih@magellanhealth.com
Cc: psychsoulman@gmail.com

Tue, Apr 30, 2019 at 7:30 PM

Requestor Name: Michael Dekker
Requestor Company: Southwest Network/AZSAM
Requestor Address1 : [3640 W. Osborn, Suite 1](#)
Requestor Address2:
Requestor City: Phoenix
Requestor State: AZ
Requestor ZipCode: 85019-
Requestor Email Address: psychsoulman@gmail.com
Requestor Telephone #: 954.319.8579
Requestor Fax #: ..
Confirm by Address? Yes
Confirm by E-mail? Yes
Confirm by Fax?
Representing Other? Yes
Representative of:
Non-affiliated/private?
Statement of No Conflicts:Yes

Disclosures:

Organization1/Role1 : /
Organization2/Role2: /
Organization3/Role3: /
Organization4/Role4: /

Summary of Testimony: Correlation of buprenorphine based medications with the Seriously Mentally Ill. I would like to be able to provide a long acting injectible based buprenorphine product for Seriously Mentally Ill (SMI) patients. I can explain why it would be clinically appropriate and best practice in this population, who is already familiar with long acting injectible medications.

Drug/Product: Sublocade or any other long acting injectible based buprenorphine products.

Therapeutic Drug Class: Opioid Agonist Treatment for Opioid Use Disorder/Dependence.

Confidentiality Notice This electronic message transmission contains information belonging to Magellan Health, its subsidiaries or affiliates, that is solely for the recipient named above and which may be confidential or privileged. MAGELLAN HEALTH, its subsidiaries or affiliates, EXPRESSLY PRESERVES AND ASSERTS ALL PRIVILEGES AND IMMUNITIES APPLICABLE TO THIS TRANSMISSION. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of this communication is STRICTLY PROHIBITED. If you have received this electronic transmission in error, please notify us by telephone at . Thank you.